© 2022 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Recommendations for counseling and managing patients’ lipid levels with newer treatments as prophylaxis against cardiovascular events.
January 14th 2022
The value of interdisciplinary research and multidisciplinary care of patients at high risk for cardiovascular events.
The standard of care for managing high cholesterol levels.
January 26th 2022
Recommendations for establishing relationships and talking with patients about primary and secondary prevention against cardiovascular events.
Criteria and types of health care professionals who may screen patients at high risk for cardiovascular disease.
February 2nd 2022
Approaches to counseling patients with high cholesterol levels on goals of therapy and the role of lifestyle changes as prevention against cardiovascular events.
What to know about the efficacy of statin therapies used as cholesterol-lowering therapy.
February 9th 2022
The role of ezetimibe and PCSK9 inhibitors as treatment for patients who are statin intolerant or require add-on therapy to help reduce cholesterol levels.
Opportunities to reduce costs and improve accessibility to therapies used for hypercholesterolemia and prophylaxis against cardiovascular events.
February 16th 2022
An overview of the REDUCE-IT trial of icosapent ethyl for the management of triglycerides and prevention of cardiovascular events.
Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.